ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2025

Phase I, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, in Patients With Metastatic Castration-Resistant Prostate Cancer.

Rahul R Aggarwal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.